Louisiana House Bill HR181

Louisiana 2017 Regular Session

• Introduced: 6/2/17
• Passed: 6/5/17

Caption

Urges and requests the Louisiana Department of Health to study the desirability and feasibility of adopting state policy to provide for review of prescription drug prices in the medical assistance program

Impact

The potential implementation of a revised state policy on prescription drug pricing could have substantial implications for Louisiana's Medicaid budget as well as the healthcare expenditures of its residents. By investigating models used in other states, such as New York and Texas, that leverage supplemental Medicaid rebates, the study could lead to reduced drug costs for the state and its beneficiaries. Furthermore, the improvement in affordability of medications may enhance compliance and adherence among patients, leading to better health outcomes overall.

Summary

House Resolution 181 urges and requests the Louisiana Department of Health to study the viability of adopting a state policy for reviewing prescription drug prices and rebates within the Medicaid program. The resolution highlights the significant burden of high prescription drug costs, particularly for vulnerable populations such as senior citizens, individuals with disabilities, and those with chronic conditions. The goal is to explore methods to provide fair access to necessary prescription drugs, which are crucial for maintaining health and managing illnesses.

Sentiment

The sentiment surrounding HR 181 appears to be supportive among lawmakers, as it passed unanimously with 100 votes in favor and no opposition. This consensus indicates a recognition across party lines of the importance of addressing the healthcare cost crisis, particularly regarding prescription drug affordability. However, there remains caution as members may be wary of the challenges involved in policy adaptation and the political implications of regulating pharmaceutical pricing.

Contention

Despite the generally positive reception of HR 181, potential contentions may arise as the study progresses and recommendations are made. Questions may emerge around the balance between ensuring affordable access to medications while maintaining an environment that encourages pharmaceutical innovation and industry compliance. Stakeholders such as drug manufacturers and healthcare providers may express concerns about how changes to prescription drug pricing and rebate structures might affect service delivery and availability.